Stocks
AgomAb Therapeutics NVAGMB
NASDAQHealthcareBiotechnology$9.11
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing monoclonal antibodies for fibrotic diseases, with a lead candidate targeting the AXL receptor in idiopathic pulmonary fibrosis. Investors track it for its potential in a high-unmet-need therapeutic area and its ongoing Phase 1/2 trials.
52W Range: $7.92-$17.82
Congressional Interest in AgomAb Therapeutics NV (AGMB)
No congressional trades have been disclosed for AgomAb Therapeutics NV (AGMB) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading AGMB?
No congressional trades found for this stock.